Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPF300 for epistaxis in hereditary hemorrhagic telangiectasia
jRCT2071230066Phase 3Completed
- Sponsor
- Fujimoto Pharmaceutical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) and epistaxis comparing FPF300 arm with Placebo to FPF300 arm (2 arms). Primary endpoints: Change in Epistaxis Severity Score from baseline and Adverse events. Started Nov 2023; status: completed.
02
Drugs
topiroxostat
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxis
Beyond the preview
Go deeper on jRCT2071230066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230066.